Received Apr 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | J32PB | LA |
administered the adjuvant without having it reconstituted with the vaccine; administered the adjuvant without having it reconstituted with the vaccine; This non-serious case was reported by a other health professional via sales rep and described the occurrence of inappropriate dose of vaccine administered in a 81-year-old female patient who received Herpes zoster (Shingrix) (batch number J32PB, expiry date 31-MAR-2027) for prophylaxis. Concurrent medical conditions included hyperlipidemia. Concomitant products included atorvastatin. On 15-APR-2025, the patient received the 1st dose of Shingrix (left deltoid). On 15-APR-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate dose of vaccine administered (Verbatim: administered the adjuvant without having it reconstituted with the vaccine) and inappropriate preparation of medication (Verbatim: administered the adjuvant without having it reconstituted with the vaccine). The outcome of the inappropriate dose of vaccine administered and inappropriate preparation of medication were not applicable. Additional Information: GSK Receipt Date: 15-APR-2025 The health care professional reported that a patient administered the adjuvant without having it reconstituted with the vaccine, which led inappropriate preparation of medication and inappropriate dose of vaccine administered. There was no anything would like to share about the primary disease. The patient was taking it as a preventive measure. There was no anything would like to share about a complicating disease. Patient was taking it as a preventive measure.
Hyperlipidemia
Atorvastatin